covimmune tm page

What makes us unique

The COVID-19 pandemic has fundamentally and irrevocably changed the world. 

At the time of writing, there have been 22.3 million cases worldwide, and more than 784,000 people have died. Every country is being impacted, and the end is not yet in sight – a vaccine is not estimated to be available until at least 2021 and possibly 2022. 

So, how do we treat patients and keep frontline healthcare workers safe?

At Aegros, we have an answer.

We are developing a COVID-19 hyperimmune treatment called Covimmune that can give frontline healthcare workers passive immunity to the virus.

How does it work?

When people contract COVID-19, their immune systems enter a state of hyperactivity to combat the illness. People who recovered from COVID-19 have antibodies to the virus and it is these COVID-19-fighting antibodies Aegros is turning into Covimmune to supply passive immunity – temporary (3-6 months ) protection from the virus – for frontline healthcare workers.

There is significant scientific research backing this approach including the Mayo Clinic and Johns Hopkins University. Aegros will be testing this via its clinical trial in conjunction with Princess Alexandria Hospital (PAH) in Brisbane and Royal North Shore Hospital (RNS) in Sydney.

We have acquired a 4,500m2 TGA-approved facility in Sydney which we are upgrading specifically for plasma fractionation. 

Should these trials, which we expect to complete by the end of the year, prove successful, our ElectroSeparation technology and hyperimmune products will be used to treat COVID-19 patients and provide passive immunity to frontline healthcare workers both in Australia and around the world by early 2021. 

The opportunity for Aegros is clear and the returns on your investment could be astronomical, given every single economy in the world is being severely impacted by the virus. Current fractionation techniques are costly and inefficient in a world with a global plasma shortage. 

Aegros has the advantage of being a small and agile biotech that can deliver a clinical treatment in early 2021, way faster than any other option.

The even better news? Once the pandemic is over, our technology can easily create hyperimmune products for a wide range of diseases and illnesses, from rabies to Middle Eastern Respiratory Virus (MERS). The sky is the limit.

We are supremely confident our technology and products will help stop the spread of COVID-19 and further diseases beyond this pandemic.